This demonstrated in vivo proof-of-concept that selective Hsp90α/β inhibition with a small molecule could affect brain Htt levels and hence supports the continued study of the development of Hsp90α/β isoform-selective therapeutics as a strategy to treat HD and other CNS disorders. The gene discussed is HSP90AA1; the disease is central nervous system disorder.